| AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin SC Penchala, S Connelly, Y Wang, MS Park, L Zhao, A Baranczak, ... Proceedings of the National Academy of Sciences 110 (24), 9992-9997, 2013 | 165 | 2013 |
| A biomimetic approach for enhancing the in vivo half-life of peptides SC Penchala, MR Miller, A Pal, J Dong, NR Madadi, J Xie, H Joo, J Tsai, ... Nature chemical biology 11 (10), 793-798, 2015 | 128 | 2015 |
| Molecular basis of traditional Chinese medicine in cancer chemoprevention S Wang, S Penchala, S Prabhu, J Wang, Y Huang Current drug discovery technologies 7 (1), 67-75, 2010 | 93 | 2010 |
| Genetic variations and gene expression of transporters in drug disposition and response Y Huang, S Penchala, AN Pham, J Wang Expert Opinion on Drug Metabolism & Toxicology 4 (3), 237-254, 2008 | 27 | 2008 |
| CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE MM Alhamadsheh, MS Park, WK Chan, X LI, SC Penchala, MR Miller US Patent 20,160,045,609, 2016 | 5* | 2016 |
| Pharmacogenomic characterization of ABC transporters involved in Multidrug Resistance AN Pharm, S Penchala, RA Graf, J Wang, Y Huang Multidrug Resistance: Biological and Pharmaceutical Advance in the …, 2008 | 5 | 2008 |
| Systems for stabilizing and delivering active agents MM Alhamadsheh, MS Park, WK Chan, X Li, SC Penchala, MR Miller US Patent 10,172,959, 2019 | 4 | 2019 |
| Enhanced active agents MM Alhamadsheh, MS Park, WK Chan, X Li, SC Penchala, MR Miller US Patent 10,363,318, 2019 | 3 | 2019 |
| Delivering enhanced active agents MM Alhamadsheh, MS Park, WK Chan, X Li, SC Penchala, MR Miller US Patent 10,596,269, 2020 | 2 | 2020 |
| Lipid‐Based and Self‐Emulsifying Oral Drug Delivery Systems S Penchala, AN Pham, Y Huang, J Wang Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications …, 2011 | 2 | 2011 |
| Characterization of AG10, a potent stabilizer of transthyretin, and its application in enhancing in vivo half-life of therapeutic peptides SC Penchala | 1 | 2016 |
| Enhanced SN-38 anticancer agent MM Alhamadsheh, MS Park, WK Chan, X Li, SC Penchala, MR Miller US Patent 11,129,902, 2021 | | 2021 |
| Enhanced anticancer agent MM Alhamadsheh, MS Park, WK Chan, X Li, SC Penchala, MR Miller US Patent 10,772,967, 2020 | | 2020 |
| Structure-Activity Relationship (SAR) for AG10, a Potential Therapeutic Agent for Cardiac Amyloidosis. SCP M Alhamadsheh, J Miles, T Cox, M Miller Northern California College of Clinical Pharmacy (NCCCP) 4th Annual PharmD …, 2015 | | 2015 |
| Development of AG10 Analogs as a Potential Therapy for Transthyretin Cardiac Amyloidosis SCP M Alhamadsheh, V Loi, M Molina, K Zhao, M Miller Northern California College of Clinical Pharmacy (NCCCP) 4th Annual PharmD …, 2015 | | 2015 |
| Covalent modification of AG10 as a longer acting, more potent stabilizing agent of transthyretin SCP M Alhamadsheh, JMX Hsieh, M Canevari, M Miller Northern California College of Clinical Pharmacy (NCCCP) 4th Annual PharmD …, 2015 | | 2015 |
| Evaluation of AG10 as a Potential Therapy for Transthyretin Cardiac Amyloidosis S Penchala, M Alhamadsheh, M Miller, MS Park, W Chan, I Graef | | 2015 |
| Preclinical evaluation studies of AG10, a potential therapeutic agent for transthyretin cardiac amyloidosis SC Penchala, M M, MS Park, WK Chan, I Graef, MM Alhamadsheh AAPS Annual Meeting, San Diego, 2014 | | 2014 |
| A potent stabilizer of transthyretin as a potential therapeutic agent for familial amyloid cardiomyopathy SC Penchala, S Connelly, Y Wang, MS Park, L Zhao, N Reixach, ... Gordon Research conference: High Throughput Chemistry & Chemical Biology …, 2013 | | 2013 |
| A New Class of Drugs Targeting Transthyretin Cardiac Amyloidosis SC Penchala, Y Wang, H Thanukrishnan, WK Chan, A MM AAPS Annual Meeting, Chicago, 2012 | | 2012 |
